Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 7, 1997, Pages 567-584

  Rohatagi, Shashank ^a,b   Barrett, Jeffrey S ^a   Dewitt, Kimberly E ^a   Morales, Richard J ^a  

^a Somerset Pharmaceuticals   (United States)

^b DMPK   (United States)

Author keywords

Pharmacokinetic model; Selegiline; Transdermal delivery

Indexed keywords

AMPHETAMINE; DRUG METABOLITE; METHAMPHETAMINE; MONOAMINE OXIDASE B INHIBITOR; SELEGILINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOKINETICS; SKIN; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; AMPHETAMINE; AMPHETAMINES; ANTIPARKINSON AGENTS; AREA UNDER CURVE; HUMANS; MALE; METHAMPHETAMINE; MODELS, BIOLOGICAL; MONOAMINE OXIDASE INHIBITORS; PILOT PROJECTS; REGRESSION ANALYSIS; SELEGILINE;

EID: 0030881523     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199710)18:7<567::AID-BDD49>3.0.CO;2-7     Document Type: Article

References (34)

1. J. D. Elsworth, V. Glover, G. P. Reynolds, M. Sandier, A. J. Lees, P. Phuapradit, K. M. Shaw, G. M. Stern and P. Kumar. Deprynl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology, 57. 33-38 (1978).
2. The Parkinson's Study Group. Effect of deprynl on the progression of disability in early Parkinson's disease. N. Engl. J. Med., 321. 1364-1371 (1989).
3. V. V. Myllylä, K. A. Sotaniemi, J. A. Vuorinen and K. H. Heinonen, Selegiline as initial treatment in de novo Parkinsonian patients. Neurology, 42. 339-343 (1992).
4. J. Knoll, R - (-)-deprenyl (selegiline. MoverganR) facilitates the activity of the nigostriatal dopaminergic neuron. J Neural Transm., 25 (suppl,). 45-66. 198.
5. P. Chrisp, G. J. Mammen and E. M. Sorkin. Selegiline: a review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1. 228-248 (1991).
6. P. Vezina, E. Mohr and D. Grimes, Deprenyl in Parkinson's Disease: mechanisms, neuroprotective effect, indications and adverse effects. Can J Neural. Sci., 19, 142-146 (1992).
7. T. Yoshida, Y. Yamada, T. Yamamoto and I. Kuroiwa, Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Xenobiolica, 16, 29-136 (1986).
8. K. Magyar and L. Tothfulusi, Pharmacokinetic aspects of deprenyl effects. Pol. J. Pharmacol. Pharm., 36. 373-384(1984).
9. 14C-Jumex. A Study Report, Orion Corporation Farmos, Turku, 1981
10. T. Yoshida, T. Oguro and Y. Kuroiwa, Hepatic and extrahepatic metabolism of deprnyl, a selective monoamine oxidase (MAO) B inhibitor of amphetamines in rats: sex and strain differences. Xenobiotica, 17. 957-963 (1987).
11. C. Oh, B. Murray, N. Bhattacharya and W. G. Tatton, (-)-deprenyl alters the survival of adult murine facial motoneurons after axotomy: increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants. J. Neurosci. Res., 38. 64-74 (1994).
12. J. S. Barrett, A. R. DiSanto, P. J. Thomford. E. M. Larsen, M. J. Palazzolo and R. J. Morales, Toxicology and toxicokinetic evaluation of a selegiline transdermal system in the dog. Biopharm. Drug Disposit. in press (1996).
13. J. S. Barren, T. J. Hochadel, R. J. Morales, S. Rohatagi, K E. DeWitt and A. R. DiSanto. Pharmacokinctics and safety of a transdermal system relative to single dose oral administration in elderly men and women. Am. J. Ther. in press (1996).
14. R (selegiline hydrochloride). Pharmacokinetics of selegiline after fast and fed state. Am. J. Ther., 3. 298-313 (1996).
15. I. Mahmood, D. K. Peters and W. D. Mason, The pharmacokinetics and bioavailability of selegiline in the dog. Biopharm. Drug Disposit., 15, 653-664 (1994).
16. M. D. Berry, A. V. Juorio and L. A. Paterson, Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog, Neurobiol., 44, 141-161 (1994).
17. P. T. Solo and W. G. Tatton, Deprenyl reduces the death of motoneurons caused by axotomy J. Neurosci. Res., 31, 394-400, 1992.
18. S. Rohatagi, J. S. Barrett, K. E. DeWitt, B. S. Lessard and R. J. Morales, Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system. Biopharm. Drug Ditposii., in press (1996).
19. R. Methods Find Exp. Clin. Pharmacol., 11(3), 173-178 (1989).
20. K. Kubota and H. I. Maibach, A compartmental model for percutaneous absorption: compatibility of lag time and steady-state flux with diffusion model J. Pharm. Sci., 81(9), 863-865 (1992).
21. T. Ogiso, Y. Ito, M. Iwaki and H. Atago, A pharmacokinetic model for the percutaneous absorption of indomethacin and prediction of drug disposition kinetics. J. Pharm. Sci., 78(4). 319-323 (1989).
22. L. L. Hall and P. V. Shah, In Vivo methods for determining percutaneous absorption and metabolism of zenobiotics: Indirect methods. In Methods far Skin Absorption. B. W. Kemppainen and W. G. Reifenrath (Eds), Chemical Rubber Company, Boca Raton. FL. 1990, pp. 100-109.
23. R. L. Bronaugh and J. I. Maibach (Eds). Percutaneous Absorption (Mechanism-methodology drug delivery) 2nd Edn., Dekker, New York, 1989.
24. K. Kubota, J. Ademola and H. I. Maibach. Simultaneous diffusion and metabolism of betamcthasone 17-valerate in the living skin. J. Pharm. Sci., 84(12), 1478-1481 (1995).
25. P. J. M. Klippert and J. Noordhoek, The area under the curve of metabolites for drugs and metabolites cleared by the liver and extrahepatic organs: its dependence on the administration route of precursor drug. Drug Metab. Disposit., 13(1), 97-101 (1985).
26. J. B. Houston and G. Taylor, Drug metabolite concentration time profiles: influence of route of drug administration. Br J. Clin. Pharmacol., 17, 385-394 (1984).
27. Scientist. Micromath User's Handbook. Salt Lake City. UT, 1995.
28. D. Lessard, F. Beaudry and A. Niggebrugge, A new high sensitivity HPLC MS MS method for the determination of selegiline and desmethylselegiline in human plasma. Pharm. Res., 11 (suppl.): S-17 (1994).
29. F. C. Lam, C. T. Hung and D. G. Perrier, Estimation of variance for harmonic mean half-lives. J. Pharm. Sci., 74(2), 229-231 (1985).
30. SAS, Cary, NC.
31. R (nicotine transdermal system). J. Clin. Pharmacol., 33, 161-168 (1993).
32. J. Ademola, C. A. Chow, R. C. Wester and H. I. Maibach, Metabolism of propranolol during percutaneous absorption in human skin. J. Pharm. Sci., 82(8), 767-770 (1993).
33. J. Ademola, E. Bloom, Maczulack and H. I. Maibach, Skin penetration and metabolism: Comparative evaluation of skin equivalent, cell culture, and human skin. J. Toxicol. Cut. Ocular Toxicol., 12(2). 129-138 (1993).
34. S. Rohatagi, J. S. Barrett, L. J. McDonald, E. M. Morris and J. Darnow. In Vitro percutaneous absorption in various species and metabolism by human skin of selegiline and its in vivo implications. Pharm. Res., 13, 5-417 (1996).